{
    "clinical_study": {
        "@rank": "132934", 
        "acronym": "CREDIT-II", 
        "arm_group": [
            {
                "arm_group_label": "EXCEL DES", 
                "description": "Use EXCEL DES implatationas as control group,Implant DES for CAD cases"
            }, 
            {
                "arm_group_label": "EXCEL-II DES", 
                "description": "EXCEL-II DES implantation as control group,Implant DES for CAD cases"
            }
        ], 
        "biospec_descr": {
            "textblock": "Endpoint Classification: Safety/Efficacy Study Enrollment: 416 cases [Anticipated]"
        }, 
        "biospec_retention": "None Retained", 
        "brief_summary": {
            "textblock": "The purpose of this Randomized Study to evaluate the safety and efficacy of the Excel-II DES\n      compared to the EXCEL DES in the treatment of patients with de novo coronary artery lesions."
        }, 
        "brief_title": "EXCEL-II Stent Vesus EXCEL Stent to Treat the Patients With de Novo Coronary Artery Lesions.", 
        "completion_date": {
            "#text": "October 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Disease", 
            "Myocardial Ischemia", 
            "Coronary Disease", 
            "Heart Diseases", 
            "Cardiovascular Diseases", 
            "Arteriosclerosis", 
            "Arterial Occlusive Diseases", 
            "Vascular Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arterial Occlusive Diseases", 
                "Arteriosclerosis", 
                "Cardiovascular Diseases", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases", 
                "Ischemia", 
                "Vascular Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary end point is to observe in-stent late lumenn loss after 9 months of the stent\n      implantation.\n\n      This study is based on non-inferior assumption (vs. EXCEL-II V EXCEL Stent), requring all of\n      end points reach statictic significance.\n\n      Quality assurance plan that addresses data validation and registry procedures, including any\n      plans for site monitoring and auditing.\n\n      Data checks to compare data entered into the registry against predefined rules for range or\n      consistency with other data fields in the registry.\n\n      Source data verification to assess the accuracy, completeness, or representativeness of\n      registry data by comparing the data to external data sources (e.g., medical records, paper\n      or electronic case report forms, or interactive voice response systems).\n\n      Data dictionary that contains detailed descriptions of each variable used by the registry,\n      including the source of the variable, coding information if used  and normal ranges if\n      relevant.\n\n      Standard Operating Procedures to address registry operations and analysis activities, such\n      as patient recruitment, data collection, data management, data analysis, reporting for\n      adverse events, and change management.\n\n      Sample size assessment to specify the number of participants or participant years necessary\n      to demonstrate an effect.\n\n      Plan for missing data to address situations where variables are reported as missing,\n      unavailable, \"non-reported,\" uninterpretable, or considered missing because of data\n      inconsistency or out-of-range results Statistical analysis plan describing the analytical\n      principles and statistical techniques to be employed in order to address the primary and\n      secondary objectives, as specified in the study protocol or plan."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        1.18yrs\u2264Age\u226475yrs . 2.stability and unstable angina pectoris (AP), chronic myocardial\n        infarction (OMI) or confirmed myocardial ischemia; 3.De novo lesion at native coronary\n        artery(Up to two target lesions). 4.Lesion length \u226432mm. 5.RVD 2.5mm\uff5e4.0mm. 6.DS%\u226570% by\n        visual test. 7.Coronary artery bypass surgery (coronary artery bypass grafting) patients.\n        8.Subjects are willing to follow the specified requirements follow-up. 9.To understand the\n        purpose of the trial and willing to sign informed consent and accept clinical follow-up.\n\n        Exclusion Criteria:\n\n          1. AMI within 7 days.\n\n          2. CTO (TIMI 0), the left main lesion, ostial lesion and transplant vascular lesions,\n             the bifurcation lesion (reference collateral blood vessel diameter of 2.5 mm or\n             higher), stent restenosis lesions and to deal with three pathological changes;\n\n          3. Severe calcified lesion unable to predilate.\n\n          4. The distortion of the stent was hampered by lesions.\n\n          5. NYHA\u2265\u2162 or LVEF\uff1c40%.\n\n          6. Prior PCI within 1 year.\n\n          7. Pregnancy or lactation, and planning pregnancy or lactation.\n\n          8. Subjects have bleeding tendency or blood coagulation dysfunction or PCI\n             contraindications, or anticoagulant therapy taboo or can't continue to take DAPT at\n             least 1 year.\n\n          9. There are other diseases (such as cancer,malignant tumor ,congestive heart\n             failure,organ transplantation or candidate) or abuse history (alcohol cocaine heroin,\n             etc.), scheme compliance is poor, interference related data explanation or the\n             limited life (< 1 year).\n\n         10. To aspirin heparin clopidogrel cobalt chromium alloy rapamycin PLA polymer contrast\n             agent of one of allergy.\n\n         11. Serious liver and kidney function are not complete subject(ALT and AST were three\n             times greater than the upper limit of normal).\n\n         12. Before enrolling to participate in other clinical trials and not reached the primary\n             endpoint.\n\n         13. Non-compliant subject and could not finish the trial in accordance with the\n             requirements of the subjects."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "This study will plan for a total of 416 patients with primary, in situ coronary artery\n        lesions (all of the patients was selected in different blood vessels, a total of up to two\n        target disease Variable and each target lesion 1 stents, such as placing stents need more\n        than one in the operation, require the use of the same brand of stents, mix does not\n        recommend the same patients Other brand support, unless save extra stents.) Choose lesions\n        reference diameter of 2.5 mm to 2.5 mm (visual), each lesion length 32 mm or less\n        (visual), participants must conform to the standard can be selected."
            }
        }, 
        "enrollment": {
            "#text": "416", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02057978", 
            "org_study_id": "CREDIT-II-131105"
        }, 
        "intervention": [
            {
                "arm_group_label": "EXCEL DES", 
                "description": "Implant DES for CAD cases", 
                "intervention_name": "EXCEL DES implatation", 
                "intervention_type": "Procedure", 
                "other_name": "Implant DES for CAD cases"
            }, 
            {
                "arm_group_label": "EXCEL-II DES", 
                "description": "Implant DES for CAD cases", 
                "intervention_name": "EXCEL-II DES implantation", 
                "intervention_type": "Procedure", 
                "other_name": "Implant EXCEL-II DES for CAD cases"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chlorhexidine", 
                "Chlorhexidine gluconate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Late Lumen Loss", 
            "MACE", 
            "Death", 
            "TLF", 
            "Thrombosis(definite or probable )"
        ], 
        "lastchanged_date": "February 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shenyang", 
                    "country": "China", 
                    "state": "Liaoning", 
                    "zip": "110015"
                }, 
                "name": "Shenyang Northern Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "2", 
        "official_title": "A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II Sirolimus Eluting Stent vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients With de Novo Coronary Artery Lesions .( CREDIT II Trial )", 
        "overall_official": {
            "affiliation": "Shenyang Northern Hospital", 
            "last_name": "Han Yaling, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To observe in-stent late lumen loss after 9 months of stent implantation", 
            "measure": "9 months in-stent late lumen loss", 
            "safety_issue": "Yes", 
            "time_frame": "9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02057978"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "9-m in stent, proximal stent edge, the distal edge segment defined in the restenosis rate, 9-m after lesions within the segment late lumen loss percentage and the diameter of the restenosis degree", 
                "measure": "9-m in-segment diameter restenosis rate", 
                "safety_issue": "Yes", 
                "time_frame": "9 months"
            }, 
            {
                "description": "Device oriented composite of cardiac death, MI, or ischemia-driven TLR at 1m, 6m, 12m,18m and annually up to 5 yrs", 
                "measure": "Device success rates , lesion success rates , clinical success rates  Device, lesion, & clinical success rates  Device, lesion, & clinical success rates  Target Lesion Failure", 
                "safety_issue": "Yes", 
                "time_frame": "1m,6m,9m,12m,18m and annually to 5years"
            }, 
            {
                "description": "Definite and probable stent thrombosis according to ARC defination", 
                "measure": "Rate of stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "1m,6m,9m,12m,18m and annually up to 5 yrs"
            }
        ], 
        "source": "JW Medical Systems Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "JW Medical Systems Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "February 2014"
    }
}